Skip to main content

Packaging, labelling and marketing of pharmaceuticals has evolved rapidly in India, with concerns about ‘deceptive similarity’ at the helm. Our Pharma Dossier (Vol. 1) discusses trade mark jurisprudence in light of the primary factor – the consumer.

Whereas differentiation on the basis of a name may have become more constrictive, creative use of unconventional marks and branding exercises by pharmaceutical companies has aided the creation of unique identities. Useful, with the rate e-pharmacies are disrupting traditional distribution models.

 

To read more, contact us at email@anandandanand.com

Most Recent

News & Insights

VIEW ALL
News & Updates, Thought Leadership
Jan 30, 2026

First published by Lexology. Authors: Safir Anand and Omesh Puri In today’s innovation‑driven economy, design rights have become a core element of

Proposed Reforms to India’s Design Protection Framework
News & Updates, Thought Leadership
Jan 17, 2026

‘First published on Asia IP’ By: Pravin Anand, Madhu Rewari and Ansh Maggo With the increasing commercialization of intellectual property in India,

Arbitrability of Intellectual Property Disputes in India
News & Updates, Thought Leadership
Jan 15, 2026

First published by Lexology. Authors: Safir Anand, Mudit Kaushik and Sehr Anand The handling of price sensitive corporate information has become increasingly

The Regulatory Cost of Informal Digital Disclosures
News & Updates
Jan 02, 2026

First published by Lexology. Authors: Pravin Anand, Saif Khan, Shobhit Agarwal and Prajjwal Kushwaha A. Background B. Legal Issues Addressed C. Directions

Landmark Ruling On Domain Name Fraud and Systematic Reforms in Digital Commerce